Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.62 |
| ▸ | KLK1 | P06870 | 1/20 | 0.60 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.60 |
| ▸ | PDE4A | P27815 | 3/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2526576 | 0.91 | PDE4B (0.75) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL16863674 | 0.87 | CA1 (0.62) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3472698 | 0.86 | PDE4B (0.85) | PDE4BKLK1KLK5PDE4APDE4C | |
| SCHEMBL3474688 | 0.82 | PDE4A (0.80) | PDE4BKLK1KLK5PDE4APDE4C | |
| SCHEMBL15010953 | 0.82 | KLK1 (0.61) | PDE4BKLK1KLK5PDE4APDE4C | |
| SCHEMBL2527062 | 0.81 | PDE4B (0.67) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL7864845 | 0.81 | PDE4B (0.60) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL13470651 | 0.81 | PDE4A (0.78) | PDE4BKLK1KLK5PDE4APDE4C | |
| SCHEMBL2527696 | 0.81 | PDE4B (0.66) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL8378720 | 0.81 | PDE4B (0.68) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285384-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2009140309-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009140309-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | PDE4B 1890/4885KLK1 1578/4885KLK5 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.